The "2025 Xi'an Digestive Forum and the 30th Shaanxi Functional Gastrointestinal Diseases Academic Conference and the Diagnosis and Treatment of Brain-Gut Interaction Abnormal Diseases and Research Progress Training Course" was successfully held at the Gastrointestinal Motility Center of the Second Affiliated Hospital of Xi'an Jiaotong University in Huayu Hotel, Xi'an from April 11 to 13, 2025. The conference was hosted by the Beijing Health Promotion Association, undertaken by the Second Affiliated Hospital of Xi'an Jiaotong University and the Shaanxi Key Laboratory of Gastrointestinal Motility Diseases, and co-organized by the Gastrointestinal Motility Group of the Digestive Branch of the Shaanxi Medical Association and the Neurogastroenterology Professional Committee of the Chinese Society of Research Hospitals.

This conference covers hot topics and progress in abnormal brain-gut interaction diseases and digestive diseases, with a special focus on detection techniques, diagnosis and treatment strategies, and the latest multidisciplinary treatment methods for functional gastrointestinal diseases such as gastroesophageal reflux disease and chronic constipation. Domestically renowned scholars are invited to give special reports on the latest progress in this field.

In this meeting, Professor Dai Fei from the Second Affiliated Hospital of Xi'an Jiaotong University gave a special report entitled "Chronic Constipation Diagnosis and Treatment Standards from Domestic and International Guidelines". Combining domestic and international guidelines, he introduced in detail the epidemiology, hazards, diagnosis and treatment of chronic constipation. Professor Dai Fei pointed out in his report: "The main treatments for chronic constipation include lifestyle adjustment, drug therapy, and biofeedback therapy. Drug therapy includes the use of bulk laxatives (such as calcium polycarbophil), osmotic laxatives, prokinetic agents, secretagogues, etc."

To further strengthen exchanges and cooperation, Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd. (hereinafter referred to as "Suzhou Chung-Hwa Chemical & Pharmaceutical") attended the conference with its brand Libofei ^® calcium polycarbophil, set up a beautiful booth, and prepared relevant academic materials and patient education tools for participants, such as a collection of professional clinical guidelines for bowel management and a collection of clinical application literature on calcium polycarbophil, patient education manuals, and stool diaries. These professional and interesting "clever" tools can help doctors have a deeper understanding of the clinical diagnosis and treatment trends related to constipation, facilitate doctors' clinical prescriptions, and improve their control over the patient's treatment process.

As a representative of bulk laxatives, Libofei^® calcium polycarbophil has an important professional position in the field of digestive health. Its main ingredient, calcium polycarbophil, absorbs water and swells in the intestine to form a hydrophilic gel, which increases the water content and volume of the stool, making the stool fluffy, soft and easy to excrete, thereby effectively relieving various constipation symptoms, such as constipation caused by irritable bowel syndrome, functional constipation, constipation caused by benign anal diseases, constipation in postoperative patients, etc.

Through the exchanges at the 2025 Xi'an Digestive Forum and the 30th Shaanxi Province Functional Gastrointestinal Diseases Academic Conference and the Diagnosis and Treatment of Brain-Gut Interaction Abnormal Diseases and Research Progress Training Course, Suzhou Chung-Hwa Chemical & Pharmaceutical has obtained valuable industry-leading dynamic information, helping the company to accurately grasp market trends and optimize its R&D strategic layout. At the same time, Suzhou Chung-Hwa Chemical & Pharmaceutical's active participation demonstrates its industry responsibility in the treatment and research of digestive system diseases, and has made positive contributions to the digestive field.

About Suzhou Chung-Hwa Chemical & Pharmaceutical

Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd. was established in April 1993, and the Yong'an Road factory was officially opened in 2014. The factory is located in Suzhou National High-tech Industrial Development Zone. It is a modern pharmaceutical company invested and established by Taiwan China Chemical Pharmaceutical Co., Ltd. Since its establishment, Suzhou Chung-Hwa Chemical & Pharmaceutical has won more than 50 annual awards. In 2020, it won the Advanced Enterprise Economic Contribution Award issued by Hushuguan Economic and Technological Development Zone, and Chairman Wu Suhuan won two awards for important contribution entrepreneurs. Over the years, it has been successively rated as a high-tech enterprise, a demonstration enterprise for the transformation of scientific and technological innovation results, and a responsible enterprise for paying tribute to the fight against the epidemic and ensuring supply.

Suzhou Chung-Hwa Chemical & Pharmaceutical has excellent R&D and production capabilities. It is one of the earliest pharmaceutical companies in China to pass GMP certification. It uses the most advanced equipment and testing instruments, relies on the strength of Taiwan's China Chemical Pharmaceutical Research Institute, and integrates cross-strait R&D resources. The main drug categories currently include: digestive system drugs, cardiovascular system drugs, skeletal muscle system drugs, endocrine system drugs, anti-infective drugs and other fields.